P. Berthaud

1.9k total citations
42 papers, 1.3k citations indexed

About

P. Berthaud is a scholar working on Pulmonary and Respiratory Medicine, Hematology and Genetics. According to data from OpenAlex, P. Berthaud has authored 42 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 17 papers in Hematology and 13 papers in Genetics. Recurrent topics in P. Berthaud's work include Chronic Myeloid Leukemia Treatments (14 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Gastrointestinal Tumor Research and Treatment (11 papers). P. Berthaud is often cited by papers focused on Chronic Myeloid Leukemia Treatments (14 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Gastrointestinal Tumor Research and Treatment (11 papers). P. Berthaud collaborates with scholars based in France, Switzerland and United Kingdom. P. Berthaud's co-authors include Jean‐Yves Blay, Catherine Delbaldo, Axel Le Cesne, David Pérol, Florence Duffaud, María Rios, Michel Tulliez, Isabelle Ray‐Coquard, Martine Amiot and Régis Bataille and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

P. Berthaud

41 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P. Berthaud France	14	498	465	427	409	311	42	1.3k
Daniel A. Rushing United States	20	771 1.5×	81 0.2×	286 0.7×	564 1.4×	50 0.2×	42	1.5k
Rodrigo Ruiz‐Soto United States	16	544 1.1×	63 0.1×	526 1.2×	438 1.1×	96 0.3×	61	1.3k
Chueh‐Chuan Yen Taiwan	19	377 0.8×	83 0.2×	105 0.2×	386 0.9×	69 0.2×	58	930
César Serrano Spain	24	1.3k 2.5×	108 0.2×	1.1k 2.6×	459 1.1×	79 0.3×	103	2.1k
Alejandro Majlis Chile	14	1.9k 3.7×	116 0.2×	637 1.5×	1.3k 3.2×	144 0.5×	20	2.4k
Gina Z. D’Amato United States	16	1.0k 2.0×	49 0.1×	538 1.3×	447 1.1×	39 0.1×	75	1.3k
Isabelle Moullet France	15	260 0.5×	376 0.8×	35 0.1×	720 1.8×	300 1.0×	22	1.5k
Jeff White United Kingdom	16	279 0.6×	64 0.1×	89 0.2×	363 0.9×	43 0.1×	53	898
Brian Turpin United States	18	750 1.5×	64 0.1×	37 0.1×	506 1.2×	134 0.4×	55	1.4k
Heinz Dürk Germany	14	275 0.6×	165 0.4×	27 0.1×	991 2.4×	767 2.5×	30	1.7k

Countries citing papers authored by P. Berthaud

Since Specialization

Citations

This map shows the geographic impact of P. Berthaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Berthaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Berthaud more than expected).

Fields of papers citing papers by P. Berthaud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Berthaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Berthaud. The network helps show where P. Berthaud may publish in the future.

Co-authorship network of co-authors of P. Berthaud

This figure shows the co-authorship network connecting the top 25 collaborators of P. Berthaud. A scholar is included among the top collaborators of P. Berthaud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Berthaud. P. Berthaud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Pein, F, Ross Pinkerton, P. Berthaud, et al.. (2007). Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours. European Journal of Cancer. 43(14). 2074–2081. 11 indexed citations

2.

Titier, Karine, Stéphane Picard, Dominique Ducint, et al.. (2005). Quantification of Imatinib in Human Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry. Therapeutic Drug Monitoring. 27(5). 634–640. 84 indexed citations

3.

Ray‐Coquard, Isabelle, David Pérol, Florence Duffaud, et al.. (2005). Prognostic factors for progression free and overall survival in advanced GIST: Results from the BFR14 phase III trial of the French Sarcoma Group. Journal of Clinical Oncology. 23(16_suppl). 9035–9035. 3 indexed citations

4.

Monnerat, Christian, Roger Henriksson, Thierry Le Chevalier, et al.. (2004). Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Annals of Oncology. 15(2). 316–323. 57 indexed citations

5.

Tardieu, Sophie, P. Berthaud, Mauricette Michallet, et al.. (2004). Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients. Pharmacoepidemiology and Drug Safety. 14(8). 545–553. 24 indexed citations

6.

Abuin, Gonzalo Gómez, Sylvie Bonvalot, Philippe Terrier, et al.. (2004). Intensive induction chemotherapy (API-AI regimen) followed by conservative surgery in adult patients with locally advanced soft tissue sarcoma (STS): Survival is predicted by the histological response. Journal of Clinical Oncology. 22(14_suppl). 9036–9036. 4 indexed citations

7.

Bastuji‐Garin, Sylvie, J. Revuz, Nicolas Bachot, et al.. (2003). Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients. Journal of the American Academy of Dermatology. 48(2). 201–206. 162 indexed citations

8.

Larghero, Jérôme, Thibaut Leguay, Samia Mourah, et al.. (2003). Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec®) in vitro and in vivo. Biochemical Pharmacology. 66(10). 1907–1913. 49 indexed citations

9.

Guilhot, François, Martine Gardembas, Philippe Rousselot, et al.. (2003). Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trials. Seminars in Hematology. 40(2 Suppl 2). 92–97. 9 indexed citations

10.

Gardembas, Martine, Philippe Rousselot, Michel Tulliez, et al.. (2003). Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood. 102(13). 4298–4305. 44 indexed citations

11.

Tabrizi, Reza, F-X Mahon, Pascale Cony Makhoul, et al.. (2002). Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571. Leukemia. 16(6). 1154–1159. 7 indexed citations

12.

Belloc, Françis, Pascale Cony Makhoul, François Guilhot, et al.. (2000). Detection of resistance to STI571 in patients with BCR-ABL positive acute leukemia and chronic myeloid leukemia blast crisis. 1. 47116. 1 indexed citations

13.

Lortholary, Alain, É. Jadaud, & P. Berthaud. (1999). [Bisphosphonates and bone metastases].. PubMed. 86(9). 732–8. 2 indexed citations

14.

Pujol, Jean-Louis, Jean‐Yves Douillard, Alain Rivière, et al.. (1997). Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.. Journal of Clinical Oncology. 15(5). 2082–2089. 56 indexed citations

15.

Chevalier, Thierry Le, J.L. Pujol, V. Alberola, et al.. (1997). 39 Six year follow up of the European Multicentre Randomised Study comparing Navelbine (NVB) alone vs NVB + Cisplatin (CDDP) vs Vindesine (VDS) + CDDP in 612 patients (pts) with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 18. 13–13. 4 indexed citations

16.

Berthaud, P., et al.. (1993). [Phase I trial of recombinant human granulocyte-macrophage colony stimulating factor. Results in patients with advanced tumors].. PubMed. 80(5). 418–30. 3 indexed citations

17.

Berthaud, P., Thierry Le Chevalier, Pierre Ruffiè, et al.. (1992). Phase I–II study of vinorelbine (Navelbine®) plus cisplatin in advanced non-small cell lung cancer. European Journal of Cancer. 28(11). 1863–1865. 41 indexed citations

18.

Berthaud, P., Thierry Le Chevalier, J. Bérille, et al.. (1989). Phase II study of pirarubicin in advanced non-small cell lung cancer. European Journal of Cancer and Clinical Oncology. 25(9). 1337–1338. 7 indexed citations

19.

Chevalier, Thierry Le, S. Gouva, E. Quoix, et al.. (1989). Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma. European Journal of Cancer and Clinical Oncology. 25(11). 1651–1652. 12 indexed citations

20.

Berthaud, P., Thierry Le Chevalier, J. Bérille, et al.. (1989). Phase II study of pirarubicin in advanced non-small cell lung cancer. European Journal of Cancer and Clinical Oncology. 25(10). 1507–1508. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact